Autopsy report · NCT02296476
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
Cause of deathFutility
“This study was terminated due to lack of clinical activity and not due to safety reasons.”
Life of this trial
- Ran for about 1 year before it stopped.
- 12 participants enrolled.
- Results were posted on the registry 2 years 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Sponsor type
- Industry
- Conditions
- Glioblastoma Multiforme
- Interventions
- Birabresib
- Participants
- 12
Trials that died the same way
- Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
“The study was terminated due to lack of efficacy.” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
“The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
“This study was terminated for reasons not related to efficacy or safety”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.